Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months
Rhea-AI Summary
Fresenius Medical Care (NYSE:FMS) plans a new share buyback program with a total volume of around EUR 1 billion, to be executed in tranches over 12 months from launch.
The program, authorized by the May 21, 2026 AGM, is expected to start soon and follows completion of a prior EUR 1 billion buyback on April 30, 2026. According to the company, the initiative is part of its capital allocation framework, complements dividends, and is supported by strong operating cash-flow generation.
Positive
- New share buyback program of around EUR 1 billion over 12 months
- Program follows completion of prior EUR 1 billion buyback on April 30, 2026
- Buyback complements dividend payments within stated capital allocation framework
- Management cites strong operating cash-flow generation enabling the new buyback
Negative
- None.
News Market Reaction – FMS
In the May 26 session, FMS declined 0.28%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Buybacks Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Buyback acceleration | Positive | +1.4% | Accelerated second tranche of EUR 1 billion share buyback program. |
| Aug 11 | Buyback tranche launch | Positive | +0.2% | Announced first tranche of up to EUR 600 million within EUR 1 billion program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior buyback announcements have been followed by modest positive price reactions, indicating markets previously viewed these capital returns constructively.
Recent history shows Fresenius Medical Care repeatedly using share repurchases within its capital allocation framework. In August 2025, it launched a first tranche of up to EUR 600 million as part of a EUR 1 billion buyback. In January 2026, it accelerated the second tranche, planning around EUR 415 million of repurchases. Both events saw small positive one-day moves, framing today’s new program as a continuation of that strategy.
Key Terms
dialyzers medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Total volume of the share buyback is around EUR 1 billion over 12 months
- Share buyback expected to begin in the near future
BAD HOMBURG,
The share buyback program is based on the authorization to purchase and use treasury shares granted by the Company's Annual General Meeting on May 21, 2026. It is expected to begin in the near future and only a few weeks after the previous share buyback program was successfully completed on April 30, 2026. As part of FME's capital allocation framework, regular share buyback programs complement dividend payments and reflect the Company's continued focus on disciplined capital allocation and value creation.
Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care AG, said, "The new share buyback program reflects our unwavering commitment to create value and return capital to shareholders. Launching a new share buyback program shortly after successfully completing our initial
Martin Fischer, Chief Financial Officer of Fresenius Medical Care, said, "The new share buyback program is enabled by our strong operating cash-flow generation and financial discipline. Allocating capital to share buybacks delivers attractive and sustainable returns for shareholders."
Information to previous FME share buyback programs can be found here: Share buyback | Fresenius Medical Care
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
dominik.heger@freseniusmedicalcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-announces-new-share-buyback-program-with-a-total-volume-of-around-eur-1-billion-with-phased-execution-over-12-months-302781709.html
SOURCE Fresenius Medical Care Holdings, Inc.